|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DIS3L |
Gene summary for DIS3L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DIS3L | Gene ID | 115752 |
| Gene name | DIS3 like exosome 3'-5' exoribonuclease | |
| Gene Alias | DIS3L1 | |
| Cytomap | 15q22.31 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8TF46 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 115752 | DIS3L | LZE4T | Human | Esophagus | ESCC | 3.39e-06 | 2.90e-01 | 0.0811 |
| 115752 | DIS3L | LZE7T | Human | Esophagus | ESCC | 2.42e-03 | 3.33e-01 | 0.0667 |
| 115752 | DIS3L | LZE8T | Human | Esophagus | ESCC | 2.12e-02 | 1.49e-01 | 0.067 |
| 115752 | DIS3L | P1T-E | Human | Esophagus | ESCC | 4.74e-05 | 3.12e-01 | 0.0875 |
| 115752 | DIS3L | P2T-E | Human | Esophagus | ESCC | 1.23e-19 | 3.13e-01 | 0.1177 |
| 115752 | DIS3L | P4T-E | Human | Esophagus | ESCC | 2.63e-06 | 2.30e-01 | 0.1323 |
| 115752 | DIS3L | P5T-E | Human | Esophagus | ESCC | 2.12e-04 | 9.85e-02 | 0.1327 |
| 115752 | DIS3L | P8T-E | Human | Esophagus | ESCC | 3.20e-15 | 2.93e-01 | 0.0889 |
| 115752 | DIS3L | P9T-E | Human | Esophagus | ESCC | 2.63e-07 | 1.64e-01 | 0.1131 |
| 115752 | DIS3L | P10T-E | Human | Esophagus | ESCC | 8.08e-18 | 3.03e-01 | 0.116 |
| 115752 | DIS3L | P11T-E | Human | Esophagus | ESCC | 5.51e-06 | 3.31e-01 | 0.1426 |
| 115752 | DIS3L | P12T-E | Human | Esophagus | ESCC | 2.89e-14 | 3.15e-01 | 0.1122 |
| 115752 | DIS3L | P15T-E | Human | Esophagus | ESCC | 3.30e-13 | 3.72e-01 | 0.1149 |
| 115752 | DIS3L | P16T-E | Human | Esophagus | ESCC | 1.04e-23 | 4.10e-01 | 0.1153 |
| 115752 | DIS3L | P20T-E | Human | Esophagus | ESCC | 1.26e-08 | 2.84e-01 | 0.1124 |
| 115752 | DIS3L | P21T-E | Human | Esophagus | ESCC | 2.59e-07 | 1.48e-01 | 0.1617 |
| 115752 | DIS3L | P22T-E | Human | Esophagus | ESCC | 8.36e-11 | 2.42e-01 | 0.1236 |
| 115752 | DIS3L | P23T-E | Human | Esophagus | ESCC | 6.71e-10 | 2.92e-01 | 0.108 |
| 115752 | DIS3L | P24T-E | Human | Esophagus | ESCC | 4.67e-06 | 1.44e-01 | 0.1287 |
| 115752 | DIS3L | P26T-E | Human | Esophagus | ESCC | 3.44e-10 | 2.29e-01 | 0.1276 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0009896 | Colorectum | AD | positive regulation of catabolic process | 180/3918 | 492/18723 | 4.33e-16 | 1.94e-13 | 180 |
| GO:1903311 | Colorectum | AD | regulation of mRNA metabolic process | 117/3918 | 288/18723 | 1.69e-14 | 4.23e-12 | 117 |
| GO:0031331 | Colorectum | AD | positive regulation of cellular catabolic process | 156/3918 | 427/18723 | 4.68e-14 | 1.05e-11 | 156 |
| GO:0006401 | Colorectum | AD | RNA catabolic process | 102/3918 | 278/18723 | 8.64e-10 | 6.76e-08 | 102 |
| GO:0044270 | Colorectum | AD | cellular nitrogen compound catabolic process | 147/3918 | 451/18723 | 3.35e-09 | 2.23e-07 | 147 |
| GO:0046700 | Colorectum | AD | heterocycle catabolic process | 145/3918 | 445/18723 | 4.37e-09 | 2.84e-07 | 145 |
| GO:0006402 | Colorectum | AD | mRNA catabolic process | 87/3918 | 232/18723 | 4.40e-09 | 2.84e-07 | 87 |
| GO:0034655 | Colorectum | AD | nucleobase-containing compound catabolic process | 133/3918 | 407/18723 | 1.56e-08 | 9.12e-07 | 133 |
| GO:0019439 | Colorectum | AD | aromatic compound catabolic process | 146/3918 | 467/18723 | 7.48e-08 | 3.84e-06 | 146 |
| GO:1901361 | Colorectum | AD | organic cyclic compound catabolic process | 153/3918 | 495/18723 | 8.23e-08 | 4.18e-06 | 153 |
| GO:0061013 | Colorectum | AD | regulation of mRNA catabolic process | 64/3918 | 166/18723 | 1.44e-07 | 6.59e-06 | 64 |
| GO:0043487 | Colorectum | AD | regulation of RNA stability | 63/3918 | 170/18723 | 9.17e-07 | 3.12e-05 | 63 |
| GO:0006417 | Colorectum | AD | regulation of translation | 141/3918 | 468/18723 | 1.32e-06 | 4.22e-05 | 141 |
| GO:0043488 | Colorectum | AD | regulation of mRNA stability | 59/3918 | 158/18723 | 1.50e-06 | 4.66e-05 | 59 |
| GO:1903313 | Colorectum | AD | positive regulation of mRNA metabolic process | 44/3918 | 118/18723 | 3.20e-05 | 5.87e-04 | 44 |
| GO:0000956 | Colorectum | AD | nuclear-transcribed mRNA catabolic process | 40/3918 | 112/18723 | 2.11e-04 | 2.79e-03 | 40 |
| GO:0061014 | Colorectum | AD | positive regulation of mRNA catabolic process | 32/3918 | 87/18723 | 4.81e-04 | 5.27e-03 | 32 |
| GO:0061157 | Colorectum | AD | mRNA destabilization | 30/3918 | 84/18723 | 1.24e-03 | 1.09e-02 | 30 |
| GO:0050779 | Colorectum | AD | RNA destabilization | 30/3918 | 88/18723 | 2.83e-03 | 2.12e-02 | 30 |
| GO:0140014 | Colorectum | AD | mitotic nuclear division | 78/3918 | 287/18723 | 6.48e-03 | 4.05e-02 | 78 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301824 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
| hsa0301834 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
| hsa030182 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
| hsa030183 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DIS3L | SNV | Missense_Mutation | c.1301C>T | p.Ser434Leu | p.S434L | Q8TF46 | protein_coding | tolerated(0.58) | benign(0.006) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| DIS3L | SNV | Missense_Mutation | c.181C>G | p.Pro61Ala | p.P61A | Q8TF46 | protein_coding | deleterious(0.01) | probably_damaging(0.941) | TCGA-B6-A0I8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| DIS3L | SNV | Missense_Mutation | novel | c.2341N>A | p.Glu781Lys | p.E781K | Q8TF46 | protein_coding | deleterious(0.03) | benign(0.238) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| DIS3L | SNV | Missense_Mutation | novel | c.1830C>G | p.Phe610Leu | p.F610L | Q8TF46 | protein_coding | tolerated(1) | benign(0) | TCGA-PL-A8LV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| DIS3L | insertion | Frame_Shift_Ins | novel | c.1795_1796insC | p.Gly599AlafsTer7 | p.G599Afs*7 | Q8TF46 | protein_coding | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| DIS3L | insertion | Frame_Shift_Ins | novel | c.1796_1797insAAATGGGTTAAATTTTCATGTAGTAATATACTATTTTTTA | p.Leu601GlyfsTer18 | p.L601Gfs*18 | Q8TF46 | protein_coding | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| DIS3L | insertion | Frame_Shift_Ins | novel | c.2103_2104insG | p.His702AlafsTer24 | p.H702Afs*24 | Q8TF46 | protein_coding | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| DIS3L | insertion | Nonsense_Mutation | novel | c.2104_2105insGTCTCCCTCTGTTGCTGGCTTTTTAAAGTCAGCTAAA | p.His702ArgfsTer9 | p.H702Rfs*9 | Q8TF46 | protein_coding | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| DIS3L | deletion | Frame_Shift_Del | novel | c.2340delN | p.Glu781SerfsTer9 | p.E781Sfs*9 | Q8TF46 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| DIS3L | SNV | Missense_Mutation | c.1690G>A | p.Glu564Lys | p.E564K | Q8TF46 | protein_coding | deleterious(0.04) | benign(0.307) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |